Evidence map›Paper›PMID 37000328›Full record

ArticleInternational journal of hematology2023

Severe systemic inflammation mimicking TAFRO syndrome following COVID-19.

Misato Tane, Hideki Kosako, Hiroki Hosoi, Kayoko Tabata, Takayuki Hiroi, Kosuke Osawa, Ryuta Iwamoto, Shogo Murata, Toshiki Mushino, Shin-Ichi Murata and 3 more

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. TAFRO Syndrome and COVID-19.Biomedicines · 2024
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Misato Tane *Department of Hematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.
Hideki Kosako *Department of Hematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.
Hiroki HosoiDepartment of Hematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan. h-hosoi@wakayama-med.ac.jp.ORCID http://orcid.org/0000-0002-8682-7476
Kayoko TabataDepartment of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan.
Takayuki HiroiDepartment of Internal Medicine, Kainan Municipal Medical Center, Wakayama, Japan.
Kosuke OsawaDepartment of Nephrology, Wakayama Medical University, Wakayama, Japan.
Ryuta IwamotoDepartment of Human Pathology, Wakayama Medical University, Wakayama, Japan.
Shogo MurataDepartment of Hematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.
Toshiki MushinoDepartment of Hematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.
Shin-Ichi MurataDepartment of Human Pathology, Wakayama Medical University, Wakayama, Japan.
Shin-Ichi ArakiDepartment of Nephrology, Wakayama Medical University, Wakayama, Japan.
Takao FujiiDepartment of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan.
Takashi SonokiDepartment of Hematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.
Wakayama Medical University · JPKitakyushu Municipal Medical Center · JP

Funding

Japan Society for the Promotion of Science KAKENHI (21K16248)
6 · The paper itself

Abstract

TAFRO syndrome is a rare systemic inflammatory disease. Its pathogenesis mainly involves excessive cytokine secretion and autoimmune dysfunction. Although its etiology is unclear, some viral infections have been reported to cause it. Here, we report a case of severe systemic inflammation mimicking TAFRO syndrome that arose after COVID-19. A 61-years-old woman suffered from a continuous fever, ascites, and edema after contracting COVID-19. She developed progressive thrombocytopenia, renal failure, and elevated C-reactive protein levels. She was tentatively diagnosed with multisystem inflammatory syndrome in adults (MIS-A) and received steroid pulse therapy. However, she exhibited worsening fluid retention and progressive renal failure, which are not typical of MIS-A. A bone marrow examination showed reticulin myelofibrosis and an increased number of megakaryocytes. Although a definitive diagnosis of TAFRO syndrome was not made according to current diagnostic criteria, we determined that her symptoms were clinically consistent with those of TAFRO syndrome. Combination therapy, including steroid pulse therapy, plasma exchange, rituximab, and cyclosporine, improved her symptoms. There are pathological similarities between hyperinflammation that arises after COVID-19 and TAFRO syndrome in terms of the associated cytokine storms. COVID-19 may have triggered the development of systemic inflammation mimicking TAFRO syndrome in this case.

Indexed as

Castleman DiseaseCOVID-19Renal InsufficiencyAdultEdemaFemaleHumansMiddle AgedSteroidsSystemic Inflammatory Response SyndromeSteroidsCOVID-19Cytokine stormInterleukin-6TAFRO syndrome

Identifiers

PMID37000328
PMCPMC10063432
OpenAlexW4362475926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.